Page last updated: 2024-10-15

3-hydroxykynurenine and Huntington Disease

3-hydroxykynurenine has been researched along with Huntington Disease in 11 studies

3-hydroxykynurenine: RN given refers to cpd without isomeric designation
3-hydroxykynurenine : A hydroxykynurenine that is kynurenine substituted by a hydroxy group at position 3.
hydroxykynurenine : A hydroxy-amino acid that is kynurenine substituted by a single hydroxy group at unspecified position. A "closed" class.

Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)

Research Excerpts

ExcerptRelevanceReference
"The brain levels of the endogenous excitotoxin quinolinic acid (QUIN) and its bioprecursor, the free radical generator 3-hydroxykynurenine (3-HK), are elevated in early stage Huntington disease (HD)."7.73Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. ( Bates, GP; Graham, RK; Guidetti, P; Hayden, MR; Leavitt, BR; MacDonald, ME; Schwarcz, R; Slow, EJ; Wheeler, VC; Woodman, B, 2006)
"Quinolinic acid is an agonist at the population of glutamate receptors which are sensitive to N-methyl-D-aspartate (NMDA), and kynurenic acid is an antagonist at several glutamate receptors."6.42Tryptophan metabolites and brain disorders. ( Clark, CJ; Darlington, LG; Forrest, CM; Mackay, GM; Stone, TW, 2003)
"The brain levels of the endogenous excitotoxin quinolinic acid (QUIN) and its bioprecursor, the free radical generator 3-hydroxykynurenine (3-HK), are elevated in early stage Huntington disease (HD)."3.73Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. ( Bates, GP; Graham, RK; Guidetti, P; Hayden, MR; Leavitt, BR; MacDonald, ME; Schwarcz, R; Slow, EJ; Wheeler, VC; Woodman, B, 2006)
"Boosting KYNA levels, through interference with the KP enzymes or through application of prodrugs/analogs with high bioavailability and potency, is a promising clinical approach."2.82Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword? ( Ostapiuk, A; Urbanska, EM, 2022)
"Quinolinic acid is an agonist at the population of glutamate receptors which are sensitive to N-methyl-D-aspartate (NMDA), and kynurenic acid is an antagonist at several glutamate receptors."2.42Tryptophan metabolites and brain disorders. ( Clark, CJ; Darlington, LG; Forrest, CM; Mackay, GM; Stone, TW, 2003)
"3-Hydroxykynurenine was substantially and significantly increased in all three brain areas studied in Huntington's disease, but not significantly increased in the cortex in Alzheimer's disease, when compared to matched controls."1.28Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease. ( Pearson, SJ; Reynolds, GP, 1992)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19901 (9.09)18.7374
1990's2 (18.18)18.2507
2000's4 (36.36)29.6817
2010's3 (27.27)24.3611
2020's1 (9.09)2.80

Authors

AuthorsStudies
Ostapiuk, A1
Urbanska, EM1
Winkler, D1
Beconi, M1
Toledo-Sherman, LM1
Prime, M1
Ebneth, A1
Dominguez, C1
Muñoz-Sanjuan, I1
Sathyasaikumar, KV2
Stachowski, EK1
Amori, L1
Guidetti, P4
Muchowski, PJ2
Schwarcz, R5
Campesan, S1
Green, EW1
Breda, C1
Kyriacou, CP1
Giorgini, F1
Stone, TW1
Mackay, GM1
Forrest, CM1
Clark, CJ1
Darlington, LG1
Bates, GP1
Graham, RK1
Hayden, MR1
Leavitt, BR1
MacDonald, ME1
Slow, EJ1
Wheeler, VC1
Woodman, B1
Guilarte, TR1
Eastman, CL1
Reddy, PH1
Tagle, DA1
Pearson, SJ2
Reynolds, GP2

Reviews

2 reviews available for 3-hydroxykynurenine and Huntington Disease

ArticleYear
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
    CNS neuroscience & therapeutics, 2022, Volume: 28, Issue:1

    Topics: Alzheimer Disease; Animals; Brain; Excitatory Amino Acid Antagonists; Humans; Huntington Disease; Ky

2022
Tryptophan metabolites and brain disorders.
    Clinical chemistry and laboratory medicine, 2003, Volume: 41, Issue:7

    Topics: AIDS Dementia Complex; Brain Diseases; Central Nervous System Diseases; Humans; Huntington Disease;

2003

Other Studies

9 other studies available for 3-hydroxykynurenine and Huntington Disease

ArticleYear
Development of LC/MS/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO).
    Journal of biomolecular screening, 2013, Volume: 18, Issue:8

    Topics: Animals; Cell Line; CHO Cells; Chromatography, Liquid; Cricetulus; Dogs; Drug Discovery; Enzyme Assa

2013
Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.
    Journal of neurochemistry, 2010, Volume: 113, Issue:6

    Topics: Age Factors; Animals; Brain; Chromatography, High Pressure Liquid; Disease Models, Animal; Female; H

2010
The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease.
    Current biology : CB, 2011, Jun-07, Volume: 21, Issue:11

    Topics: Animals; Animals, Genetically Modified; Disease Models, Animal; Drosophila melanogaster; Huntington

2011
3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease?
    Advances in experimental medicine and biology, 2003, Volume: 527

    Topics: Aged; Animals; Butyrates; Case-Control Studies; Cerebellum; Corpus Striatum; Frontal Lobe; Humans; H

2003
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice.
    Neurobiology of disease, 2006, Volume: 23, Issue:1

    Topics: Age Factors; Animals; Brain Chemistry; Chromatography, Gas; Chromatography, High Pressure Liquid; Di

2006
Is 3-hydroxykynurenine an endogenous neurotoxin in Huntington's disease?
    Journal of the neurological sciences, 1993, Volume: 116, Issue:2

    Topics: Humans; Huntington Disease; Kynurenine; Neurotoxins

1993
Early kynurenergic impairment in Huntington's disease and in a transgenic animal model.
    Neuroscience letters, 2000, Apr-14, Volume: 283, Issue:3

    Topics: Aged; Animals; Disease Models, Animal; Humans; Huntingtin Protein; Huntington Disease; Kynurenine; M

2000
Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease.
    Neuroscience letters, 1992, Sep-14, Volume: 144, Issue:1-2

    Topics: Aged; Alzheimer Disease; Brain Chemistry; Cerebral Cortex; Corpus Striatum; Female; Humans; Huntingt

1992
Increased brain 3-hydroxykynurenine in Huntington's disease.
    Lancet (London, England), 1989, Oct-21, Volume: 2, Issue:8669

    Topics: Brain Chemistry; Cerebral Cortex; Humans; Huntington Disease; Kynurenine; Tryptophan

1989